Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.
Böckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M, Seebacher E, Ulbrich M, Wilnit A, Metz C, Heidemeier A, Bley T, Werner R, Buck A, Einsele H, Kortüm KM, Beilhack A, Rasche L. Böckle D, et al. Among authors: heidemeier a. Br J Haematol. 2022 Aug;198(3):515-522. doi: 10.1111/bjh.18249. Epub 2022 May 18. Br J Haematol. 2022. PMID: 35582835
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Rasche L, et al. Among authors: heidemeier a. Theranostics. 2019 Jul 9;9(16):4756-4763. doi: 10.7150/thno.33289. eCollection 2019. Theranostics. 2019. PMID: 31367255 Free PMC article.
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Steinhardt MJ, Zhou X, Krummenast F, Meckel K, Nickel K, Böckle D, Messerschmidt J, Knorz S, Dierks A, Heidemeier A, Lapa C, Einsele H, Rasche L, Kortüm KM. Steinhardt MJ, et al. Among authors: heidemeier a. Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420980258. doi: 10.1177/2058738420980258. Int J Immunopathol Pharmacol. 2020. PMID: 33353443 Free PMC article.
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, Rasche L. Da Vià MC, et al. Among authors: heidemeier a. Nat Med. 2021 Apr;27(4):616-619. doi: 10.1038/s41591-021-01245-5. Epub 2021 Feb 22. Nat Med. 2021. PMID: 33619368 Clinical Trial.
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Steinhardt MJ, Krummenast FC, Rosenwald A, Gerhard-Hartmann E, Heidemeier A, Einsele H, Topp MS, Duell J. Steinhardt MJ, et al. Among authors: heidemeier a. J Cancer Res Clin Oncol. 2022 Jan;148(1):205-214. doi: 10.1007/s00432-021-03663-x. Epub 2021 Jun 3. J Cancer Res Clin Oncol. 2022. PMID: 34085097 Free PMC article.
21 results